Invention Grant
- Patent Title: Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
-
Application No.: US15403073Application Date: 2017-01-10
-
Publication No.: US10016446B2Publication Date: 2018-07-10
- Inventor: Herriot Tabuteau
- Applicant: ANTECIP BIOVENTURES II LLC
- Applicant Address: US NY New York
- Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee Address: US NY New York
- Agency: Mashoff Brennan Laycock Gilmore
- Agent Brent A. Johnson; Yuefen Zhou
- Main IPC: A61K31/675
- IPC: A61K31/675 ; A61K31/56 ; A61K9/00
Abstract:
Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid in an acid or a salt form, or in a molecular complex can be used to treat or alleviate pain or related conditions, such as treating pain associated with Paget's disease of bone.
Public/Granted literature
Information query
